On July 4, President Donald Trump signed H.R. 1, the One Big Beautiful Bill Act, into law.
On July 3, 2025, CMS announced new opioid safety edit submission guidelines for Medicare Part D sponsors for 2026.
Medicare Part D sponsors must have concurrent drug utilization review (DUR) systems, policies, and procedures designed to ensure that a review of the prescribed drug therapy is performed before each prescription is dispensed to an enrollee in a sponsor’s Part D plan, typically at the POS or point of distribution as described in 42 CFR § 423.153(c)(2).
H.R. 1 will result in less preventive care and more preventable emergency room visits, increasing costs for everyone across the health care system and threatening hospitals with closure, which will further reduce access to critical care for American patients.
Each fall, thousands of managed care professionals gather for AMCP Nexus, a dynamic meeting you'll connect with the people, ideas, and innovations shaping the future of pharmacy and health care. Nexus 2025 is shaping up to be our most engaging and insightful gathering yet with new features, big names, and an even greater focus on connection, wellness, and professional growth.
Last week, AMCP convened a diverse group of stakeholders for its Precision Medicine Partnership Forum to examine solutions that improve access, consistency, and quality in precision oncology.
Read the Journal of Managed Care + Specialty Pharmacy (JMCP) June 2025 Issue
On June 9, HHS Secretary Robert F. Kennedy Jr. took the unprecedented step of unilaterally removing all 17 members of the Advisory Committee on Immunization Practices (ACIP).
In Kennedy v. Braidwood Management, Inc., the plaintiffs challenged the constitutionality of the USPSTF, arguing that USPSTF members should be considered “principal officers” under the Appointments Clause and, therefore, must be appointed by the President and confirmed by the Senate.
As CMS explores strategies to increase the adoption of digital health tools, AMCP urges CMS to support broader coverage of prescription digital therapeutics (PDTs) under Medicare and Medicaid. PDTs represent an emerging class of software-based treatments that deliver clinically validated therapeutic benefits, either independently or in combination with other interventions. These products can play a transformative role in improving access, especially for patients with behavioral health conditions or chronic diseases.
